Structure-guided engineering of eukaryotic Fanzor-ωRNA system enhances in vivo gene editing for dystrophin restoration in a Duchenne mouse model

Abstract Background Eukaryotic Fanzor (Fz) proteins are compact RNA-guided endonucleases homologous to prokaryotic TnpB/Cas12, offering theoretical advantages for single AAV delivery. However, their low editing efficiency and poorly defined specificity in mammals have hindered therapeutic development. Results Here, we perform structure-guided engineering of Spizellomyces punctatus Fanzor1 nuclease (SpuFz1) to enhance its utility for in vivo genome editing and identify several Fanzor variants whose efficiencies are comparable or only slightly lower than widely-used miniature enAsCas12f1 and large-sized SpCas9. We demonstrate that catalytically dead dSpuFz1-v4.2 can be repurposed for CRISPRa-mediated transcriptional activation in a proof-of-concept manner. Genome-wide PEM-seq in mice reveal low translocation frequencies (below 0.05%, much lower than the background threshold set by the PEM-seq protocol), with no detected events attributable to off-target editing. GUIDE-seq analysis also confirms genome-wide low off-target profile for SpuFz1-v4.2 in human cells, with small amounts of off-target editing due to 3’ terminal sequence tolerability. Embryonic mRNA injection efficiently generates mutant mice. Crucially, single AAV9 delivery of SpuFz1-v4.2 in a humanized Duchenne muscular dystrophy model induces targeted exon skipping, restores dystrophin expression to ~ 10% of wild-type levels, and improves muscle contractile force. Conclusions Structure-guided optimization overcomes the activity barrier of eukaryotic Fanzors while maintaining low off-target effect. The engineered SpuFz1-v4.2 retains the hypercompact size necessary for single AAV packaging, establishing a robust platform for in vivo gene editing. This work positions Fanzor by a preliminary proof-of-concept therapeutic study as a viable, miniature alternative to CRISPR-Cas systems for genetic disease intervention and functional genomics.

Authors

Institutions

Publication Details

Journal
Genome biology
Published
2026-11-13
DOI
https://doi.org/10.1186/s13059-026-04332-3
Primary Topic
CRISPR and Genetic Engineering
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Structure-guided engineering of eukaryotic Fanzor-ωRNA system enhances in vivo gene editing for dystrophin restoration in a Duchenne mouse model

Zhifang Li, Chunyi Hu, Shengsheng Ma, Shuangyu Ma et al.
5 links
Genome biology
CRISPR and Genetic Engineering
article

Structure-guided engineering of eukaryotic Fanzor-ωRNA system enhances in vivo gene editing for dystrophin restoration in a Duchenne mouse model

Zhifang Li, Chunyi Hu, Shengsheng Ma, Shuangyu Ma, Jinqi Shi, Changchang Xin, Zhuang Shao, Rongrong Yang, Jiajia Lin, Guoling Li, Peng Yang, Yuan Wei, Jiaxu Hong, Xiaona Huo
article en

Abstract

Abstract Background Eukaryotic Fanzor (Fz) proteins are compact RNA-guided endonucleases homologous to prokaryotic TnpB/Cas12, offering theoretical advantages for single AAV delivery. However, their low editing efficiency and poorly defined specificity in mammals have hindered therapeutic development. Results Here, we perform structure-guided engineering of Spizellomyces punctatus Fanzor1 nuclease (SpuFz1) to enhance its utility for in vivo genome editing and identify several Fanzor variants whose efficiencies are comparable or only slightly lower than widely-used miniature enAsCas12f1 and large-sized SpCas9. We demonstrate that catalytically dead dSpuFz1-v4.2 can be repurposed for CRISPRa-mediated transcriptional activation in a proof-of-concept manner. Genome-wide PEM-seq in mice reveal low translocation frequencies (below 0.05%, much lower than the background threshold set by the PEM-seq protocol), with no detected events attributable to off-target editing. GUIDE-seq analysis also confirms genome-wide low off-target profile for SpuFz1-v4.2 in human cells, with small amounts of off-target editing due to 3’ terminal sequence tolerability. Embryonic mRNA injection efficiently generates mutant mice. Crucially, single AAV9 delivery of SpuFz1-v4.2 in a humanized Duchenne muscular dystrophy model induces targeted exon skipping, restores dystrophin expression to ~ 10% of wild-type levels, and improves muscle contractile force. Conclusions Structure-guided optimization overcomes the activity barrier of eukaryotic Fanzors while maintaining low off-target effect. The engineered SpuFz1-v4.2 retains the hypercompact size necessary for single AAV packaging, establishing a robust platform for in vivo gene editing. This work positions Fanzor by a preliminary proof-of-concept therapeutic study as a viable, miniature alternative to CRISPR-Cas systems for genetic disease intervention and functional genomics.

Genome biology
Fujian Medical University (CN), National University of Singapore (SG), Guangdong Medical College (CN), Chinese Academy of Sciences (CN), Fudan University (CN), ShanghaiTech University (CN), Eye & ENT Hospital of Fudan University (CN), Shanghai Institute of Materia Medica (CN), First Affiliated Hospital of Fujian Medical University (CN)
Good health and well-being
CRISPR and Genetic Engineering
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon